相关实验视频

Updated: Jul 18, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

可切除肝细胞癌的新辅助免疫疗法:系统性审查和元分析

Y-H Han¹, J-Q Bo, L-X Liu

¹Department of Gastroenterology and Hepatology, The First Hospital of Shanxi Medical University, Taiyuan, China. lixinliu6@hotmail.com.

European review for medical and pharmacological sciences

|August 22, 2023

概括

新辅助免疫疗法对可切除肝细胞癌 (HCC) 有望,具有显著的病理反应率和可接受的安全性. 需要进一步的大规模试验来证实其作为HCC的外科手术治疗的疗效.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
肝细胞癌研究肝细胞癌研究

背景情况:

免疫检查点抑制剂代表了肝细胞癌 (HCC) 治疗的重大进展.
正在探索新辅助免疫疗法以改善结果并减少可切除的HCC的复发.
新辅助免疫治疗可切除的HCC的临床疗效和安全性需要进一步研究.

结论:

新辅助免疫疗法证明了可切除的HCC的初步疗效和安全性,将其定位为潜在的外科手术治疗策略.
这些发现表明,新辅助免疫疗法是改善预后和减少可切除HCC的复发的有希望的选择.
更大的临床试验至关重要,以建立确定的证据,在HCC管理中广泛采用新辅助免疫疗法.

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.